+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Ocular Hypertension - Pipeline Review, H1 2020

  • ID: 5007694
  • Drug Pipelines
  • February 2020
  • Region: Global
  • 145 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Aerie Pharmaceuticals Inc
  • Angelini Group
  • Envisia Therapeutics Inc
  • Kowa Company Ltd
  • NicOx SA
  • Ocular Therapeutix Inc
  • MORE
Ocular Hypertension - Pipeline Review, H1 2020

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Ocular Hypertension - Pipeline Review, H1 2020, provides an overview of the Ocular Hypertension (Ophthalmology) pipeline landscape.

Ocular hypertension occurs when the pressure inside the eye (intraocular pressure) is higher than normal. If the aqueous humor does not flow through the trabecular meshwork properly, fluid pressure in the eye builds up, causing ocular hypertension. There are no symptoms with ocular hypertension. Risk factors include age, family history of glaucoma, lower systemic blood pressure, thinner central cornea and bleeding at the optic nerve head. Treatment includes eye drops to reduce intraocular pressure.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Ocular Hypertension - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Ocular Hypertension (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ocular Hypertension (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Ocular Hypertension and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 4, 10, 14, 5 and 7 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Ocular Hypertension (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Ocular Hypertension (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Ocular Hypertension (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Ocular Hypertension (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Ocular Hypertension (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Ocular Hypertension (Ophthalmology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Ocular Hypertension (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Ocular Hypertension (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Aerie Pharmaceuticals Inc
  • Angelini Group
  • Envisia Therapeutics Inc
  • Kowa Company Ltd
  • NicOx SA
  • Ocular Therapeutix Inc
  • MORE
  • Introduction
  • Ocular Hypertension - Overview
  • Ocular Hypertension - Therapeutics Development
  • Ocular Hypertension - Therapeutics Assessment
  • Ocular Hypertension - Companies Involved in Therapeutics Development
  • Ocular Hypertension - Drug Profiles
  • Ocular Hypertension - Dormant Projects
  • Ocular Hypertension - Discontinued Products
  • Ocular Hypertension - Product Development Milestones
  • Appendix
List of Tables
  • Number of Products under Development for Ocular Hypertension, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..2), H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Ocular Hypertension - Pipeline by Aerie Pharmaceuticals Inc, H1 2020
  • Ocular Hypertension - Pipeline by Aerpio Pharmaceuticals Inc, H1 2020
  • Ocular Hypertension - Pipeline by Allergan Plc, H1 2020
  • Ocular Hypertension - Pipeline by Angelini Group, H1 2020
  • Ocular Hypertension - Pipeline by BioIVT, H1 2020
  • Ocular Hypertension - Dormant Projects, H1 2020
  • Ocular Hypertension - Dormant Projects, H1 2020 (Contd..1), H1 2020
  • Ocular Hypertension - Discontinued Products, H1 2020
  • Ocular Hypertension - Discontinued Products, H1 2020 (Contd..1), H1 2020
List of Figures
  • Number of Products under Development for Ocular Hypertension, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Top 10 Routes of Administration, H1 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Aerie Pharmaceuticals Inc
  • Aerpio Pharmaceuticals Inc
  • Allergan Plc
  • Angelini Group
  • BioIVT
  • Chong Kun Dang Pharmaceutical Corp
  • D. Western Therapeutics Institute Inc
  • Envisia Therapeutics Inc
  • Kedalion Therapeutics Inc
  • Kowa Company Ltd
  • Laboratoires Thea SA
  • Laboratorios Sophia SA de CV
  • Lee's Pharmaceutical Holdings Ltd
  • Neurim Pharmaceuticals Ltd
  • NicOx SA
  • Novartis AG
  • Noveome Biotherapeutics Inc
  • Ocular Therapeutix Inc
  • Ocuphire Pharma Inc
  • Santen Pharmaceutical Co Ltd
  • Senju Pharmaceutical Co Ltd
  • Shenzhen Hornetcorn Bio-technology Company Ltd
  • Sun Pharma Advanced Research Company Ltd
  • Sustained Nano Systems LLC
  • Sylentis SAU
  • Taejoon Pharm Co Ltd
  • Takeda Pharmaceutical Co Ltd
  • ViSci Ltd
  • Whitecap Biosciences LLC
Note: Product cover images may vary from those shown
Adroll
adroll